NICE technology appraisal guidance
Issued: December 2012 (last modified: January 2015)
TA269

Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta269

1 Guidance

1.1 Vemurafenib is recommended as an option for treating BRAF V600 mutation‑positive unresectable or metastatic melanoma only if the manufacturer provides vemurafenib with the discount agreed in the patient access scheme.